Ye L, Guo J, Jing L P, Peng G X, Zhou K, Li Y, Li Y, Li J P, Fan H H, Song L, Zhang F K, Zhang L
Anemia Therapeutic Centre, Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
Zhonghua Xue Ye Xue Za Zhi. 2018 Feb 14;39(2):137-142. doi: 10.3760/cma.j.issn.0253-2727.2018.02.012.
To explore the life span of red blood cells (RBC) in patients with severe/very severe aplastic anemia (SAA/VSAA). Clinical data of 128 SAA/VSAA patients from November 2016 to April 2017 were retrospectively analyzed, and 13 healthy volunteers in the same period was used as normal control. The endogenous Breath Carbon Monoxide (CO) test was used to detect the life span of RBC in SAA/VSAA patients, and the effect of immunosuppressive therapy (IST) on the life span of RBC in these patients was explored. The mean life span of RBC in 51 untreated SAA/VSAA patients was (50.69±21.43) d, which was significantly shorter than that in normal controls[(111.85±31.55) d](=-6.611, <0.001). The mean life span of RBC in 77 patients treated with IST was (87.14±39.28) d. The mean life span of RBC in complete responses (CR), hematologic response (HR) and non-response (NR) patients were (106.15±32.12) d, (92.00±38.60) d and (50.44±21.56) d, respectively. The life span of RBC in patients with HR was significantly longer than that in newly diagnosed and NR patients (=7.430, <0.001; =4.846, =0.002), which was similar to that in the normal controls (=-1.743,=0.085). There was no statistical significance between CR patients and the normal controls in the mean life span of RBC (=-0.558, =0.579). No factor affecting the RBC life span was found in univariate logistical regression analyses in the newly diagnosed SAA/VSAA patients. The serum levels of IL-2R and IL-6 were much lower in HR patients than NR patients[IL-2R: 4.3×10 U/L 6.5×10 U/L, =-2.733, =0.006; IL-6: 2.6 (2.0-17.7) ng/L 6.1 (2.0-14.4) ng/L, =-2.968, =0.003]. Of the 51 newly diagnosed patients, 38 received IST and their 3-month curative effect was evaluated. Receiver operator characteristics (ROC) curve was used to analyze the predictive effect of RBC life span of untreated patients on the efficacy of IST before treatment. The cut-off point was 60 days with sensitivity of 37.5% and specificity of 86.4%. In 9 cases with life span of RBC>60 d before IST, 6 cases acquired HR, while in 29 cases with life span of RBC ≤ 60 d before IST, 10 cases acquired HR, the difference was not statistically significant (=0.128). The life span of RBC in SAA/VSAA patients was shortened, which can be improved even recovered to the normal after IST. Elevated cytokines might play a role in the pathophysiology of the shortened RBC life span in SAA/VSAA.
探讨重型/极重型再生障碍性贫血(SAA/VSAA)患者红细胞(RBC)的寿命。回顾性分析2016年11月至2017年4月期间128例SAA/VSAA患者的临床资料,并将同期13名健康志愿者作为正常对照。采用内源性呼气一氧化碳(CO)试验检测SAA/VSAA患者RBC的寿命,并探讨免疫抑制治疗(IST)对这些患者RBC寿命的影响。51例未治疗的SAA/VSAA患者RBC的平均寿命为(50.69±21.43)天,显著短于正常对照(111.85±31.55)天。77例接受IST治疗的患者RBC的平均寿命为(87.14±39.28)天。完全缓解(CR)、血液学缓解(HR)和未缓解(NR)患者RBC的平均寿命分别为(106.15±32.12)天、(92.00±38.60)天和(50.44±21.56)天。HR患者RBC的寿命显著长于新诊断患者和NR患者(=7.430,<0.001;=4.846,=0.002),与正常对照相似(=-1.743,=0.085)。CR患者与正常对照RBC的平均寿命无统计学差异(=-0.558,=0.579)。在新诊断的SAA/VSAA患者的单因素逻辑回归分析中,未发现影响RBC寿命的因素。HR患者血清IL-2R和IL-6水平显著低于NR患者[IL-2R:4.3×10 U/L 6.5×10 U/L,=-2.733,=0.006;IL-6:2.6(2.0-17.7)ng/L 6.1(2.0-14.4)ng/L,=-2.968,=0.003]。51例新诊断患者中,38例接受IST治疗并评估其3个月疗效。采用受试者工作特征(ROC)曲线分析未治疗患者RBC寿命对IST治疗前疗效的预测作用。截断点为60天,敏感性为37.5%,特异性为86.4%。IST治疗前RBC寿命>60天的9例患者中,6例获得HR,而IST治疗前RBC寿命≤60天的29例患者中,10例获得HR,差异无统计学意义(=0.128)。SAA/VSAA患者RBC寿命缩短,IST治疗后可改善甚至恢复正常。细胞因子升高可能在SAA/VSAA患者RBC寿命缩短的病理生理过程中起作用。